Post-transplant immunotherapy designed to prevent cancer recurrence.
Most stem cell transplants are performed to treat neoplasms. Yet many patients survive the transplant but die from cancer recurrence post-transplant. The incorporation of post-transplant immunotherapy offers the potential for enhanced antitumor efficacy.
Sondel
P M
PM
University of Wisconsin Comprehensive Cancer Center, Madison, USA. pmsondel@facstaff.wisc.edu
D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D020350:Graft vs Tumor Effect / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011379:Prognosis; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007166:Immunosuppressive Agents